[smartslider3 slider=”1″]Early detection of Cancer/Relapse/Recurrence can “make a real difference..”
Pre-procedure counselling is offered to determine the benefits of CTC tests..
Best Quality tests for you
RGCC CAMBISEQ™
RGCC cancer analysis, mutational burden and instability sequencing (CAMBISeq) provides next- generation sequencing analysis on both DNA and RNA. RGCC CAMBISeq can help to identify variants in more than 500 genes,
aCGH Test
The array comparative genomic hybridisation (aCGH) test is used to identify abnormalities in a genome,when either part of the genetic sequence in a chromosome is deleted or added to – that might lead to cancer.
Metastat RGCC Test
Markers on CTCs that point out the potential organ for relapse. It can help practitioners in the prognosis of metastases trends in cancer patients.
Immune Frame Test
Profile of humoral and cellular immunity and cachexia. This test uses specific cellular markers and cytokine production to detect the type/types of cells that are responsible for activation / repression of the immune system of host.
ChemoSNIP Test
This provides information about DNA mutations that can affect how humans develop cancer or cancer respond to anti-cancer drugs and treatments.
ChemoSNiP includes the study of SNPs of genes that are included in the metabolism/detoxification of cytostatic or targeted drugs that are used as cancer therapy.
When used together with data from chemosensitivity testing like Onconomics Plus, it helps to narrow the selection to the most effective and least toxic therapeutic agent.
Oncotrail RGCC Test
This test is a tailor made test for a specific type of malignancy such as breast cancer (Oncotrail for Breast), prostate (Oncotrail for Prostate), Colon, Melanoma, Lung, Sarcoma, Gastrointestinal for follow up control.
Oncotrace RGCC Test
This test will report the number of CTC’s, any positive CSC’s, and the immunophenotype of these cells.
Oncocount RGCC Test
This test will report only the number of Circulating Cancer Tumor Cells (CTC’s). It does not include any other information concerning the CTC’s or Circulating Cancer Stem Cells (CSC’s) Immunophenotyping.
Onconomics Plus RGCC Test
4. This test is the combination of both Onconomics and Onconomics extracts test, which includes conventional treatment information, Gene profiling and the Integrative Treatment information.
Onconomics Extracts Plus Test
These results will provide the information on effectiveness of the natural substances and also provide Gene Profiling information on cancer-related genes at the epigenetic level. This test can be used for patients who are opting for Integrative/Alternate cancer therapies alongside conventional medical treatments as recommended by their doctor.
Onconomics Extracts Plus test groups the natural substances based on three categories,
i) CLASS I – Testing for the direct effect of anti-cancer treatment,
ii) CLASS II – Stimulating the immune system, and
iii) CLASS III- Inhibiting proliferative signals in the cancer cells that stimulate them to grow.
Onconomics Extracts Test
This test includes only the assessment of natural substances and plant extracts for any anticancer potency. No chemotherapeutic agents tested and no tumor suppressor genes tested.
Onconomics RGCC Test
The test includes the chemosensitivity / chemoresistance assessment for cytotoxic drugs, monoclonal antibodies, and small molecules that inhibit specific targets eg.(TKI’s) and Gene profiling at Epigenetic level. No Natural substances are tested.
Best Quality Therapies for you
VAXO-Q-Re
Vaxo-Q-Re is a new advanced therapy consisting of five types of immune cells; macrophages, NK cells, dendritic cells, cytotoxic T lymphocytes and antibody producing plasma cells. Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Vaxo-Q-Re has been in development by RGCC scientists for more than five years and is now categorized as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA).
ATA – Vaccine Prep from Tumour Cell Antigens
Autologous vaccines are created from a patient’s cancer cells, which are isolated from a blood sample. The cancer cells are cultured (effectively grown) in the laboratory, where they are combined with an immuno-stimulant designed to stimulate the body’s immune system into action. The disrupted cancer cells, now called tumour cell antigens, are re-administered into the patient through a vaccine. They provide the immune system with the blueprint to eliminate any remaining cancer cells in the body. The vaccine enables the body’s immune system to target and destroy cancer cells while leaving healthy tissue untouched.
DENDRITIC CELL THERAPY
DCs are exceptionally powerful initiators of immunity, with the ability to activate an immune response more potently than any other cell in the immune repertoire. Dendritic cells are a type of antigen presenting cells (APC) that play an important role in the adaptive immune system. They have the capacity to induce a primary immune response in the inactive or resting naïve T lymphocytes. To do this DCs capture antigens from invading bodies, which they process and present on their cell surface along with the necessary co-stimulation molecules. They also contribute to the function of B cells and help maintain their immune memory.
SUPPORTIVE OLIGONUCLEOTIDE THERAPY (SOT- Apoptosis Inducer)
SOT is a personalized therapy for cancer, viruses and pathogens including Lyme Disease. The SOT has the ability to bind to a specific gene of interest that controls the cancer cell or pathogen by disrupting the critical process that promotes its survival or growth. During this therapy, we analyze a patient’s blood and create a complementary oligonucleotide sequence designed to interrupt the cells’ survival or growth. RGCC SOTs are available to RGCC Network doctors. Please contact us to discuss your requirements.
See more >
Information For PatientsWe work with cancer patients to provide a range of personalised
tests so you can choose the best treatment.
More patient information
7 Steps For RGCC Test
What Our Doctor’s Say:
Using this test helps oncologists take the possible drug out of chemo selection, increasing the likelihood of successful treatment, and reducing unnecessary toxic side effects by avoiding chemos that would not work
https://www.youtube.com/watch?v=kDXHZDOcdnQhttps://www.youtube.com/watch?v=E9QwX9V10rYhttps://www.youtube.com/watch?v=UK0jlBAhUvsEvery cancer patient is uniqueWhy choose our Tests?
CTC’S COUNT CAN BE CONSIDERED AS A PREDETERMINED PROGNOSTIC FACTOR , TO DETECT EARLY RELAPSE OR RECURRENCE CONDITIONS.
Events
Find out more about our latest research, trials and education days
[recent_post_slider design=”design-4″ arrows=”false”]
NEELI GENETIC SERVICES
Call us: +(91) 789-356-2434, +(91) 770-208-4807, +(91) 789-356-2434 (whatsapp)
Email: Office@neeligenetics.com